What's New
Health Professional and Public Communication, Notice to Hospitals
Fentanyl Transdermal Systems - New Changes to the Dose Conversion Guidelines - Janssen-Ortho Inc., Cobalt Pharmaceuticals Inc., Teva Canada Limited, Ranbaxy Pharmaceuticals Canada Inc., ratiopharm inc., Sandoz Canada Inc. and Pharmascience Inc.
The morphine dose conversion ratio (parenteral versus oral) is now of 1:3. The conversion doses of IV/IM morphine to Fentanyl Transdermal Systems (patch strengths of 75, 87 and 100 mcg/hour) were revised to “not applicable” to reflect the insufficiency of data available for guidance.
Health Professional Communication
Public Communication
Notice to Hospitals
Public Advisory
Unapproved Health Product, “POWER-MAX” May Pose Serious Health Risks
Health Canada is warning Canadians that an unapproved health product that contains sildenafil, a prescription medication was found on the Canadian market in Ontario. Sildenafil may pose serious health risks, particularly to people with heart problems.
Public Advisory
Foreign Product Alerts
Health Canada is advising consumers not to use the following foreign health products due to concerns about possible adverse reactions:
2H & 2D
Products distributed by Atlas Operations Inc.
Products distributed by Bodybuilding.com
STRO Emperor Capsules
Tian Yang Xu Huo Oral Ulcer Capsule
National Drug Scheduling Advisory Committee Meeting - March 7-8, 2010
The next meeting of the National Drug Scheduling Advisory Committee (NDSAC) is scheduled for March 7-8, 2010. The primary purpose of the meeting is to consider the following matter:
- Request for Unscheduled status for diclofenac diethylamine in preparations for topical use on the skin in concentrations of not more than the equivalent of 1% diclofenac.
[> More]